CIPROFLOXACIN AND DEXAMETHASONE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal	CIPROFLOXACIN AND DEXAMETHASONE	ciprofloxacin; dexamethasone	SUSPENSION/DROPS;OTIC	216501	ANDA	Amneal Pharmaceuticals of New York LLC	53746-831-53	1 BOTTLE, PLASTIC in 1 CARTON (53746-831-53) / 7.5 mL in 1 BOTTLE, PLASTIC	2024-03-26
Dr Reddys	CIPROFLOXACIN AND DEXAMETHASONE	ciprofloxacin; dexamethasone	SUSPENSION/DROPS;OTIC	205548	ANDA	NorthStar RxLLC	16714-628-01	1 BOTTLE, DROPPER in 1 CARTON (16714-628-01) / 7.5 mL in 1 BOTTLE, DROPPER	2022-08-01
Dr Reddys	CIPROFLOXACIN AND DEXAMETHASONE	ciprofloxacin; dexamethasone	SUSPENSION/DROPS;OTIC	205548	ANDA	Dr. Reddy's Laboratories, Inc.	43598-326-75	1 BOTTLE, DROPPER in 1 CARTON (43598-326-75) / 7.5 mL in 1 BOTTLE, DROPPER	2020-08-10
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 30, 2025

Introduction

The global pharmaceutical landscape is characterized by a complex network of suppliers producing active pharmaceutical ingredients (APIs) and finished drug formulations. With the rising demand for antibiotics and corticosteroids, Ciprofloxacin and Dexamethasone have emerged as key medications in treating bacterial infections and inflammatory conditions, respectively. Understanding the primary suppliers for these drugs is essential for stakeholders across the supply chain, including manufacturers, regulators, and healthcare providers, to ensure drug availability, quality, and supply chain resilience.

Ciprofloxacin: Overview and Major Suppliers

Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic primarily used to treat urinary tract infections, respiratory tract infections, and certain gastrointestinal bacterial infections. Since its approval, it has become one of the most widely prescribed antibiotics globally. The manufacturing of Ciprofloxacin involves synthesizing complex APIs, with several key suppliers dominating the market.

Leading API Suppliers for Ciprofloxacin

Zhejiang Hisun Pharmaceutical Co., Ltd. (China)
Hisun Pharmaceuticals is a prominent Chinese manufacturer producing Ciprofloxacin and its intermediates. Its strategic focus on the antibiotic segment has strengthened its position as a reliable API supplier globally. Hisun's manufacturing complies with Good Manufacturing Practices (GMP) and cGMP standards, facilitating export to North America, Europe, and emerging markets.
Shandong Kexing Pharmaceutical Co., Ltd. (China)
Kexing is a significant Chinese manufacturer offering Ciprofloxacin APIs with extensive exportation. The company invests heavily in R&D, ensuring product consistency and quality in accordance with international standards.
Livan Pharmaceuticals (India)
As a leading Indian API producer, Livan Pharmaceuticals supplies Ciprofloxacin to global markets, leveraging India’s reputation as the “pharmacy of the world.” Their manufacturing facilities adhere to WHO-GMP standards, facilitating exports to North America, Africa, and Southeast Asia.
Sointa Chemical (India)
Specializing in antibiotics and APIs, Sointa supplies Ciprofloxacin with a focus on quality control, offering both bulk APIs and formulations for generic drug manufacturers.
Hubei Biocause Pharmaceutical Co., Ltd. (China)
A growing player in the antibiotic API market, Hubei Biocause supplies Ciprofloxacin to global markets, emphasizing cost-effective manufacturing and regulatory compliance.

Diversification and Regional Dynamics

China dominates the Ciprofloxacin API landscape due to its large-scale manufacturing and cost competitiveness. Indian manufacturers also maintain a significant share owing to established pharmaceutical export infrastructure and quality standards. Other key regions include Europe and North America, primarily through procurement from Chinese and Indian suppliers, often via licensing agreements or import channels.

Dexamethasone: Overview and Major Suppliers

Dexamethasone, a potent corticosteroid, is used for its anti-inflammatory and immunosuppressant properties, especially in autoimmune diseases and severe COVID-19 cases. Its global demand surged during the pandemic, elevating the importance of reliable suppliers.

Leading API Suppliers for Dexamethasone

Sandoz (Novartis Group) – Switzerland
Sandoz produces Dexamethasone APIs under stringent quality controls for global distribution. Their manufacturing facilities in Europe comply with EU-GMP requirements, ensuring high-quality standards in supplied APIs.
Mylan/National Pharmaceutical Industry (Egypt)
Mylan, now part of Viatris, sources Dexamethasone from Egyptian API producers, leveraging regional manufacturing hubs that prioritize cost-efficiency and supply stability.
Srinivasa Pharmaceuticals (India)
An established Indian API manufacturer, Srinivasa produces Dexamethasone with a focus on affordability and reliability, serving international markets including Southeast Asia and Africa.
BASF SE (Germany)
BASF supplies Dexamethasone intermediates and APIs to global formulators, emphasizing innovation and high purity standards. Their advanced R&D capabilities ensure consistent API quality.
Qilu Pharmaceutical Co., Ltd. (China)
The Chinese pharmaceutical giant provides Dexamethasone APIs and intermediates, supporting both the domestic and export markets with cost-effective, quality-certified products.

Market Dynamics and Recent Trends

During the COVID-19 pandemic, the demand for Dexamethasone surged, prompting supply chain adjustments and increased production from Indian and Chinese manufacturers. Regulatory harmonization and quality assurance remain critical, especially for injectable formulations, which constitute a significant portion of Dexamethasone usage.

Regulatory Considerations and Quality Assurance

Suppliers of Ciprofloxacin and Dexamethasone must adhere to stringent regulatory standards, including US FDA, EMA, and WHO-GMP certifications. Regulatory bodies prioritize API quality to prevent substandard medicines, which can cause drug resistance (notably with antibiotics like Ciprofloxacin) or adverse effects (in corticosteroids like Dexamethasone). The credibility of suppliers hinges on compliance with these standards and transparent manufacturing practices.

Supply Chain Challenges and Strategic Implications

Global Supply Chain Disruptions:
The COVID-19 pandemic revealed vulnerabilities in sourcing APIs from major regions like China and India. These disruptions emphasize the importance of diversifying suppliers and increasing local manufacturing capacities. Several pharmaceutical companies are now investing in regional API production to ensure uninterrupted supplies.

Pricing and Cost Considerations:
Cost competitiveness is vital, especially for generic drug manufacturers. Chinese and Indian suppliers maintain a price advantage over Western manufacturers, enabling affordable medicines but necessitating strict quality audits.

Geopolitical Factors:
Trade tensions and export restrictions influence supplier stability. Governments and private companies seek to establish resilient supply chains by fostering regional manufacturing hubs and engaging in strategic procurement agreements.

Conclusion

The landscape of Ciprofloxacin and Dexamethasone suppliers reflects a geopolitical and economic mosaic, with China and India leading the API manufacturing scene. Ensuring supply chain resilience requires continuous monitoring of regulatory compliance, capacity expansion, and diversification strategies. Stakeholders must prioritize quality and transparency while adapting to evolving economic and geopolitical realities.

Key Takeaways

China dominates the Ciprofloxacin API market, with major suppliers such as Zhejiang Hisun and Shandong Kexing, supported by Indian manufacturers like Livan Pharmaceuticals.
Dexamethasone APIs are primarily supplied by Sandoz (Switzerland), BASF (Germany), and Indian and Chinese producers, with demand surging during the COVID-19 pandemic.
Regulatory compliance, especially adherence to GMP standards, remains critical for supplier credibility and global distribution.
Supply chain resilience can be enhanced through diversification, regional manufacturing investments, and maintaining strategic stockpiles.
geopolitical influences and trade policies significantly impact API procurement strategies for multinational pharmaceutical companies.

FAQs

1. Who are the top global suppliers of Ciprofloxacin API?
Chinese manufacturers such as Zhejiang Hisun Pharmaceutical and Shandong Kexing are leading global suppliers, supported by Indian producers like Livan Pharmaceuticals and Sointa Chemical.

2. Which companies are primary suppliers of Dexamethasone API?
Major suppliers include Sandoz (Switzerland), BASF (Germany), and Indian and Chinese API makers like Srinivasa Pharmaceuticals and Qilu Pharmaceutical.

3. How has the COVID-19 pandemic affected the supply of Dexamethasone?
Demand surged globally, leading to increased production from existing suppliers, especially in India and China, while highlighting the importance of diversified supply chains.

4. What are the regulatory considerations for API suppliers?
Suppliers must meet international standards such as GMP certifications from the FDA, EMA, or WHO, ensuring high-quality APIs suitable for pharmaceutical manufacturing.

5. How can pharmaceutical companies mitigate supply chain risks for these APIs?
By diversifying suppliers across regions, investing in local manufacturing capabilities, and maintaining strategic inventory reserves, companies can enhance supply chain resilience.

Sources

[1] European Medicines Agency — API manufacturing standards.
[2] World Health Organization — List of WHO-GMP certified pharmaceutical manufacturers.
[3] Novartis Sandoz official reports — API production and certifications.
[4] Indian Pharmaceutical Industry Association — API manufacturing capacity.
[5] China's National Medical Products Administration — API approval and registration data.

Suppliers and packagers for CIPROFLOXACIN AND DEXAMETHASONE